236 related articles for article (PubMed ID: 6682193)
21. Management of levodopa failures: the use of dopamine agonists.
Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
[TBL] [Abstract][Full Text] [Related]
22. D-1 and D-2 agonists in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):466-73. PubMed ID: 2960431
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Biesemeyer H; Ludin HP; Ringwald E
J Neurol; 1983; 230(1):19-23. PubMed ID: 6194269
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Parkinson's disease with lergotrile mesylate.
Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
[TBL] [Abstract][Full Text] [Related]
25. [Clinical study of pergolide in Parkinson's disease].
Gonce M; Delwaide PJ
Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
[TBL] [Abstract][Full Text] [Related]
26. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.
Giménez-Roldán S; Esteban EM; Mateo D
Clin Neuropharmacol; 2001; 24(6):346-51. PubMed ID: 11801810
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
Godwin-Austen RB; Smith NJ
J Neurol Neurosurg Psychiatry; 1977 May; 40(5):479-82. PubMed ID: 330825
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine combined with levodopa in Parkinson's disease.
Gauthier G; Martins da Silva A
Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
[TBL] [Abstract][Full Text] [Related]
29. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Montastruc JL; Schmitt L; Bagheri H
Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
[TBL] [Abstract][Full Text] [Related]
30. [Dopaminergic agonists in the treatment of Parkinson's disease].
Supiot F; Sternon J; Zegers de Beyl D
Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
[TBL] [Abstract][Full Text] [Related]
31. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
32. Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont E; Mikkelsen B; Jakobsen J
J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
[TBL] [Abstract][Full Text] [Related]
33. [Worsened orthostatic hypotension due to levodopa administration in a case of Parkinson's disease].
Kondo M; Ueda Y; Makino M; Nakajima K
Nihon Ronen Igakkai Zasshi; 2000 Mar; 37(3):255-8. PubMed ID: 10879077
[TBL] [Abstract][Full Text] [Related]
34. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Parkes JD; Debono AG; Marsden CD
J Neurol Neurosurg Psychiatry; 1976 Nov; 39(11):1101-8. PubMed ID: 1036999
[TBL] [Abstract][Full Text] [Related]
35. Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
Lera G; Vaamonde J; Muruzabal J; Obeso JA
Ann Neurol; 1990 Oct; 28(4):593-4. PubMed ID: 2252377
[No Abstract] [Full Text] [Related]
36. Long-term use of dopamine agonists in Parkinson's disease.
Jankovic J
Clin Neuropharmacol; 1985; 8(2):131-40. PubMed ID: 3891082
[No Abstract] [Full Text] [Related]
37. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
38. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
Luthra PM; Kumar JB
Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
[TBL] [Abstract][Full Text] [Related]
40. The initial treatment of Parkinson's disease should begin with levodopa.
Weiner WJ
Mov Disord; 1999 Sep; 14(5):716-24. PubMed ID: 10495031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
